404 related articles for article (PubMed ID: 15869932)
1. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
Hald A; Lotharius J
Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
[TBL] [Abstract][Full Text] [Related]
2. Inflammation in Parkinson's disease: causative or epiphenomenal?
Hald A; Van Beek J; Lotharius J
Subcell Biochem; 2007; 42():249-79. PubMed ID: 17612055
[TBL] [Abstract][Full Text] [Related]
3. [The role of JNK pathway in familial Parkinson's disease].
Jankowski M
Postepy Biochem; 2007; 53(3):297-303. PubMed ID: 18399358
[TBL] [Abstract][Full Text] [Related]
4. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
5. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?
Rogers J; Mastroeni D; Leonard B; Joyce J; Grover A
Int Rev Neurobiol; 2007; 82():235-46. PubMed ID: 17678964
[TBL] [Abstract][Full Text] [Related]
6. The influence of microglia on the pathogenesis of Parkinson's disease.
Long-Smith CM; Sullivan AM; Nolan YM
Prog Neurobiol; 2009 Nov; 89(3):277-87. PubMed ID: 19686799
[TBL] [Abstract][Full Text] [Related]
7. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
Hunter RL; Dragicevic N; Seifert K; Choi DY; Liu M; Kim HC; Cass WA; Sullivan PG; Bing G
J Neurochem; 2007 Mar; 100(5):1375-86. PubMed ID: 17254027
[TBL] [Abstract][Full Text] [Related]
8. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
9. Neuroinflammatory processes in Parkinson's disease.
Hirsch EC; Hunot S; Hartmann A
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S9-S15. PubMed ID: 15885630
[TBL] [Abstract][Full Text] [Related]
10. Iron transport in Parkinson's disease.
Hirsch EC
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
[TBL] [Abstract][Full Text] [Related]
11. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
[TBL] [Abstract][Full Text] [Related]
12. Oxidative mechanisms in nigral cell death in Parkinson's disease.
Jenner P
Mov Disord; 1998; 13 Suppl 1():24-34. PubMed ID: 9613715
[TBL] [Abstract][Full Text] [Related]
13. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation.
Teismann P; Schulz JB
Cell Tissue Res; 2004 Oct; 318(1):149-61. PubMed ID: 15338271
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action.
Kim YJ; Park HJ; Lee G; Bang OY; Ahn YH; Joe E; Kim HO; Lee PH
Glia; 2009 Jan; 57(1):13-23. PubMed ID: 18661552
[TBL] [Abstract][Full Text] [Related]
15. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.
Marchetti B; Serra PA; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Cioni S; Gennuso F; Rocchitta G; Desole MS; Mazzarino MC; Miele E; Morale MC
Ann N Y Acad Sci; 2005 Dec; 1057():296-318. PubMed ID: 16399902
[TBL] [Abstract][Full Text] [Related]
16. Neuronal pathology in Parkinson's disease.
Schulz JB; Falkenburger BH
Cell Tissue Res; 2004 Oct; 318(1):135-47. PubMed ID: 15365812
[TBL] [Abstract][Full Text] [Related]
17. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide and reactive oxygen species in Parkinson's disease.
Tieu K; Ischiropoulos H; Przedborski S
IUBMB Life; 2003 Jun; 55(6):329-35. PubMed ID: 12938735
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
Tsai SJ
Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
[TBL] [Abstract][Full Text] [Related]
20. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
